Ocugen Hits New 1-Year High, But Should Investors Buy?

Ocugen's stock price surged to a new 52-week high, but analysts are split on the company's future prospects.

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on gene therapies and vaccines, saw its stock price hit a new 52-week high of $2.67 on Tuesday. The stock closed at $2.33, up 6% for the day. Ocugen has been the subject of mixed reviews from Wall Street analysts, with some maintaining a 'buy' rating and others downgrading the stock to 'sell'.

Why it matters

Ocugen's stock price surge reflects investor optimism about the company's pipeline of gene therapies and vaccines. However, the mixed analyst views suggest there is still uncertainty around Ocugen's long-term prospects and whether the current stock price is justified.

The details

Ocugen's stock price has been volatile in recent months, with the company reporting both positive and negative news. On the positive side, Ocugen received a 'buy' rating and a $7 price target from Chardan Capital in early March. However, other analysts, such as Wall Street Zen, have downgraded the stock to 'sell'. Ocugen is currently developing gene therapies for rare inherited retinal diseases as well as vaccines for infectious diseases.

  • Ocugen's stock hit a new 52-week high of $2.67 on Tuesday, March 17, 2026.
  • The company reported its latest earnings on Wednesday, March 4, 2026.

The players

Ocugen, Inc.

A clinical-stage biopharmaceutical company focused on developing gene therapies and vaccines. The company is headquartered in Malvern, Pennsylvania.

Chardan Capital

A Wall Street research firm that maintains a 'buy' rating and $7 price target on Ocugen's stock.

Wall Street Zen

A Wall Street research firm that has downgraded Ocugen's stock to a 'sell' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must maintain a 'buy' rating on Ocugen and believe the stock has significant upside potential.”

— Chardan Capital, Research Analyst (Chardan Capital Research Report)

“Ocugen's stock is overvalued and we are downgrading it to a 'sell' rating.”

— Wall Street Zen, Research Analyst (Wall Street Zen Research Report)

What’s next

Investors will be closely watching Ocugen's upcoming pipeline updates and financial results to gauge the company's long-term prospects.

The takeaway

Ocugen's stock price surge reflects investor optimism, but the mixed analyst views suggest caution is warranted. Investors should closely monitor the company's progress on its gene therapy and vaccine programs to determine if the current valuation is justified.